Innovations in Oncology

Program Overview

The 3rd International Symposium "Innovations In Oncology" will open for registration on 26 June 2017 at 08:45 AM. On 27 June 2017 registration will be open from 08:30 AM.

Satellite Symposium (with friendly support of Roche AG)

June 26, 2017: 09:15 PM – 6:20 PM

Morning Coffee/Registration

09:15-09:25 Welcome
Stefan Frings, Roche Pharma AG /
Christof von Kalle, National Center for Tumor Diseases (NCT) Heidelberg

Tapping into External Innovation (TBC)
Gad Bitton, Roche Pharma Finance Group Mergers & Acquisitions

Data in the Real World Applied to Drug Development to Boost Innovation
Adrian Cassidy , Roche RWD-S Oncology

Integrating Big Data and NGS into Drug Development to Advance PHC
Astrid Kiermaier, Oncology Biomarker Development, Roche/Genentech

10:25-11:00 Panel Discussion

Symposium "Innovations in Oncology"

June 26, 2017: 09:15 PM – 6:20 PM

Welcome Lunch

Christa Maar, Christof von Kalle

Chairs: Rita Schmutzler (conf.), Evelin Schröck (TBC)

How Do We Interpret Familiality in Colorectal Cancer?
C. Richard Boland, University of California, San Diego

Defining the Unknown Unknowns of Colon Cancer
Richard Houlston, The Institute of Cancer Research, London

Metagenomics and the Host-Microbe Interface
Ami Bhatt, Stanford Unversity

A First World Problem: how Lifestyle Factors Influence the Risk of Developing CRC
Martha Shrubsole, Vanderbilt University Medical Center, Nashville

Coffee Break and Visual Applause

Johannes Bruns (conf.), Thomas Schnelle / Metaplan (conf.)

Johannes Bruns, German Cancer Society, Berlin       

Panel Discussion
Moderated by Thomas Schnelle, Metaplan, Hamburg       

Coffee Break and Visual Applause

The German Cancer Consortium (DKTK): An Innovative Platform for Bench-to-Bedside Research
Otmar D. Wiestler, Helmholtz Association, Berlin

Chairs: Hermann Brenner (conf.), Frank Kolligs (conf.)

Blood, Sweat, No Tears: the Liquid Biopsy of Colon Cancer
Thomas Seufferlein, University Clinics Ulm

To See or Not to See: Advances in Imaging Techniques
Maximilian Reiser, Ludwigs-Maximilians-University Munich

Hot Air or Hot Trail? Diagnosis of Diseases from Breath Tests
Hossam Haick, Technion - Israel Institute of Technology, Israel

Potential of Human Fecal Microbiota for Early Stage Detection of Colorectal Cancer  
Peer Bork, European Molecular Biology Laboratory, Heidelberg

Evening Reception

June 27, 2017: 9:00 AM – 6:10 PM

Morning Coffee

What’s App, Doc? The Power of Comprehensive Health Records
Andrew Morris, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh

Chairs: Arno Elmer (conf.), Michael Hallek (conf.)

CancerLinQ: Utilizing Real World Evidence to Improve Patient Outcomes
George Komatsoulis, ASCO CancerLinQ

Turning Data Sharing into Practice
Gerrit A. Meijer, AACR GeniE / Netherlands Cancer Institute, Amsterdam

Genetic Testing: Data Sharing and Data Complexity
Rolf Sijmons, University of Groningen                    

ColonFlag - The Implementation of a Machine Learning Algorithm to Flag Individuals Harbouring Pre-Cancerous and Cancerous Colonic Lesions within a Large Health Maintenance Organisation
Ran Goshen, Medial EarlySign, Israel

Coffee Break and Visual Applause

Moderated by Thomas Schnelle / Metaplan

Lunch Break

Chair: Justus Duyster (conf.), Jürgen Riemann (conf.)

News in Colorectal Cancer from ASCO 2017
Diana Lüftner, Charité University Clinics, Berlin

Chairs: Georg Ralle (conf.), J. Rüdiger Siewert (conf.)

14:30-14.40    Bristol-Myers Squibb GmbH & Co.KGaA, München
14:45-14:55    Merck Serono GmbH, Darmstadt
15:00-15:10    MSD SHARP & DOHME GMBH, Haar b. München
15:15-15:25    Norgine GmbH, Marburg
15:30-15:40    Olympus Deutschland GmbH, Hamburg
15:45-15:55    Pfizer Pharma GmbH, Berlin
16:00-16:10    Roche Pharma AG, Grenzach-Wyhlen

Coffee Break and Visual Applause

Chairs: Dirk Jäger (conf.), Johannes Bruns (conf.)

T-Cell Transfer Immunotherapy Targeting the Gastrointestinal Cancer Mutanome
Eric Tran, Earle A. Chiles Research Institute, Providence Cancer Center, Portland

Harnessing the Innate Immune System: Macrophage Repolarization via CCR5 Inhibition
Niels Halama, National Center for Tumor Diseases (NCT) Heidelberg/University Hospital, Heidelberg

CEA-Targeted T-Cell Bispecific Antibody and Next Generation Immunomodulators for the Treatment of Colon Cancer and Other Solid Tumors
Pablo Umaña, Roche Innovation Center, Zürich

Christof von Kalle (conf.)

Get Together